Carlsmed (NASDAQ:CARL) Stock Keeps “Buy” Rating at BTIG Research

Carlsmed (NASDAQ:CARL)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a note issued to investors on Monday, Benzinga reports. They presently have a $23.00 price objective on the stock. BTIG Research’s price objective points to a potential upside of 63.24% from the company’s previous close.

A number of other research analysts also recently commented on the company. Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings raised Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Needham & Company LLC started coverage on Carlsmed in a research note on Wednesday, July 1st. They issued a “buy” rating and a $17.00 price target for the company. Finally, Truist Financial boosted their price target on Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.25.

Carlsmed Stock Performance

Shares of CARL traded down $0.09 during midday trading on Monday, reaching $14.09. 53,832 shares of the stock were exchanged, compared to its average volume of 138,787. Carlsmed has a twelve month low of $8.50 and a twelve month high of $17.23. The company has a quick ratio of 8.66, a current ratio of 8.84 and a debt-to-equity ratio of 0.18. The company has a market cap of $384.66 million, a P/E ratio of -9.85 and a beta of 1.95. The stock’s 50 day simple moving average is $14.52 and its 200 day simple moving average is $12.07.

Carlsmed (NASDAQ:CARL) last posted its earnings results on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Carlsmed had a negative return on equity of 38.06% and a negative net margin of 57.42%.The company had revenue of $18.94 million during the quarter. On average, sell-side analysts expect that Carlsmed will post -1.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Deutsche Bank AG bought a new stake in shares of Carlsmed during the second quarter worth about $106,000. Bank of America Corp DE acquired a new position in shares of Carlsmed in the second quarter worth approximately $108,000. Alpine Woods Capital Investors LLC acquired a new position in shares of Carlsmed in the second quarter worth approximately $161,000. Bank of New York Mellon Corp acquired a new position in shares of Carlsmed in the second quarter worth approximately $181,000. Finally, Janus Henderson Group PLC lifted its stake in Carlsmed by 7.6% in the first quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock valued at $11,108,000 after buying an additional 86,834 shares during the period.

Carlsmed News Summary

Here are the key news stories impacting Carlsmed this week:

• Positive Sentiment: BTIG reaffirmed its “Buy” rating and $23 price target, implying substantial upside from the stock’s recent $14.09 level. The endorsement supports investor confidence in Carlsmed’s AI-enabled personalized spine surgery business. BTIG rating and price target
• Positive Sentiment: Carlsmed reaffirmed fiscal 2026 revenue guidance of $74 million to $78 million, a range that broadly brackets the $76.7 million analyst consensus estimate. Maintaining the outlook indicates that management has not identified a material deterioration in demand or execution. Carlsmed 2026 revenue outlook
• Neutral Sentiment: Richard Heppenstall was appointed chief financial officer effective immediately. The company did not announce a change to its revenue outlook, and the appointment could strengthen financial and operational management as Carlsmed scales. Carlsmed appoints Richard Heppenstall CFO
• Negative Sentiment: The abrupt CFO change may create short-term uncertainty around leadership continuity, financial controls, and execution. Investors may seek additional details about the outgoing CFO and the reasons for the transition, particularly because Carlsmed remains unprofitable.

Carlsmed Company Profile

Carlsmed, Inc is a medical technology company focused on improving outcomes for patients undergoing complex spinal surgery. The company develops personalized implants and surgical solutions designed to help spine surgeons address the anatomical needs of individual patients, particularly those with adult spinal deformity and other challenging spinal conditions.

Its principal product platform, aprevo, uses patient-specific planning and implant design to support spinal reconstruction procedures.